and underwent functional neck dissection, regardless of response at the end of therapy. Fifty percent (3/6) with positive Chemoradiation is increasingly becoming the standard of care pathology had a regional relapse in the neck, whereas only for node-positive squamous cell cancer of the head and neck.
C O N C L U S I O N S
tively analyzed a cohort of node-positive patients to examine pathological response as well as clinical outcome after chemora-Clinical response at 50 Gy can be an effective means of selecting diation with or without functional neck dissection.
patients for functional neck dissection. Patients with complete response at 50 Gy may be observed with a low regional recurrence rate. Those patients with a partial response should un- Neck dissection after radiation therapy has been well recognized to improve the regional control after radia-
M E T H O D S

R E S U L T S
tion alone in advanced head and neck cancer. 1 
M E T H O D S
From 1993 to 2003, 420 patients with head and neck cancer were seen at the UCLA Department of Radiation Oncology. From this initial population, we selected patients who (1) had clinically positive necks at the time of diagnosis, (2) underwent concurrent chemoradiation as their primary therapy, and (3) had no prior surgical intervention other than biopsy. Exclusionary criteria were induction chemotherapy, recurrent disease, previous radiation therapy, and radiation therapy at an outside facility. Thirty-four patients fit these criteria. In all cases, radiation therapy was performed at UCLA under the same radiation oncologist (G.J.). All patients were treated on Elekta Linear Accelerators using photonbeam irradiation for the initial 50 Gy. Boost doses to field or by electron beam with custom cutout. Median radiation dose to gross neck disease was 68.4 Gy (range: 60.4-73.8 Gy). Median dose to subclinical neck disease six hypopharynx/larynx. Table 1 provides a breakdown was 49.4 Gy (range: 46-50.5 Gy).
of sites by neck dissection status. Cisplatin-based chemotherapy was started on day Median follow-up time for all patients was 25 months one of radiation therapy. No induction chemotherapy (range: 4-88 months). Fifty percent (17/34) of patients was used. Thirty-five percent (12/34) received cisplatin were observed, and 50% underwent FND. Only one alone, and 44% (15/34) received cisplatin during radiapatient (1/17, 6%) in the observed group experienced tion therapy plus adjunctive cisplatin/5-fluorouracil. a regional recurrence, and this was a combined locoregi-The remaining patients received cisplatin plus a second onal recurrence. In the FND group, four patients (4/ agent at the discretion of the prescribing medical oncolo-17, 24%) experienced a regional recurrence. Of these gist.
dissected patients, the pathological sterilization rate was Evaluation for FND was performed by the referring 64% (11/17), meaning that 36% (6/17) had residual head and neck surgeon and treating radiation oncologist.
tumor in the neck dissection specimen. Within this CR was defined via clinical examination. Any palpable subpopulation, 50% (3/6) of the positive neck patients residual disease was defined as a PR. If the patient was developed a regional recurrence, whereas only 9% (1/ judged to have an early CR, defined as no clinical disease 11) of the patients with negative pathology developed at 50 Gy, the patient was observed. If the patient was a recurrence in the neck (Fig. 2 ). judged to have a late CR or PR, a neck dissection was
The overall recurrence rates were 35% (6/17) versus scheduled ( Fig. 1 ). Neck dissection was performed be-24% (4/17), respectively. The local recurrence rates were tween 4 and 8 weeks after completion of therapy and 11% and 17%, respectively ( Table 2) . consisted of an FND in all cases. No patients received
In terms of overall survival, two patients in the FND a modified or radical neck dissection.
group and one patient without FND died during the Follow-up care included a minimum of clinical evalustudy period. No statistically significant difference in ation at 2 weeks after the completion of therapy, following with check-ups every 3 months. Assessment for recurrence for study purposes occurred at each of these intervals until the end of the study interval. Recurrence Of 34 total patients, primary tumor sites were as follows: N3 3 5 two oral tongue, seven nasopharynx, 19 oropharynx, dissection instead of FND) may be needed for those with a PR, a hypothesis that can be looked at in future survival was observed between groups (log-rank test, P ‫ס‬ 0.34). studies. A CR at 50 Gy must be distinguished from a CR at the end of therapy. Although psychologically therapeu-
D I S C U S S I O N
tic, these patients still demonstrate residual disease, as seen by the 36% positive pathology rate in the group Clinical response at 50 Gy can be an effective means of selecting patients for FND. Those patients with a CR that underwent dissection. Brizel et al 4 demonstrated findings similar to those of our study, with a 25% posi-at 50 Gy had a regional recurrence rate of 6% with observation alone. Jaulerry et al 5 demonstrated that re-tive pathology rate after clinical CR at the end of therapy in patients with N2 stage disease. They went on to sponse at 55 Gy predicted for local control with radiation therapy alone. In the Jaulerry et al study, patients who demonstrate that a neck dissection in this group is beneficial, and that the regional recurrence rate was signifi-demonstrated a 75% or greater clinical response had a significantly higher rate of local control, a finding that cantly lower with dissection.
Emergence of positron emission tomographic scan-we took as support for our current protocol for treatment of the neck.
ning may augment the clinical evaluation, as seen from early results from several studies. 6, 7 Yao et al 7 demon-Following the most conservative approach, any patient with a finding indicative of PR at 50 Gy underwent strated a high concordance between negative positron emission tomographic findings and negative pathologi-FND, even if the patient achieved a CR at the end of therapy. From a radiobiologic perspective, the CR of cal findings (100% in eight patients). If a patient demonstrated a clinical CR at 50 Gy, a negative positron adenopathy by 50 Gy signals sensitivity to therapy, which is borne out by the fact that only one patient who emission tomographic scan may allow a clinician additional evidence to forego an FND. However, this ap-had not undergone dissection had a regional recurrence. This ''biologic selection bias'' also manifested in this proach needs additional investigation.
As concurrent chemoradiation becomes the primary study as a 23% regional recurrence rate in the dissected group. This is an important finding even if FND is treatment modality for advanced head and neck malignancy, the question of how to manage the neck is an performed by protocol in all patients, because then the response at 50 Gy may be of prognostic value. Consider-important one. Using a clinical response at 50 Gy is one potential option that should be explored, especially in ation of more aggressive surgery (e.g., modified radical 
